{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:44:32Z","timestamp":1777369472525,"version":"3.51.4"},"reference-count":41,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Theravance Biopharma R&D, Inc."}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Study Objective<\/jats:title>\n                    <jats:p>\n                      Telavancin and vancomycin are both approved for treatment of hospital\u2010acquired and ventilator\u2010associated bacterial pneumonias caused by\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      , and both agents can cause renal dysfunction. The objective of this study was to assess renal function changes by performing renal shift table analyses of telavancin\u2010 and vancomycin\u2010treated patients in phase\n                      <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\n                      trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      Retrospective, descriptive analysis of data from the safety population from the Assessment of Telavancin for Treatment of Hospital\u2010Acquired Pneumonia (\n                      <jats:styled-content style=\"fixed-case\">ATTAIN<\/jats:styled-content>\n                      ) trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>A total of 1503 adults with hospital\u2010acquired or ventilator\u2010associated bacterial pneumonia primarily caused by gram\u2010positive pathogens and who received telavancin (n\u00a0=\u00a0751) or vancomycin (n\u00a0=\u00a0752).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>\n                      Decline or improvement in creatinine clearance (CrCl) across seven defined categories (\u226430, &gt;30\u201340, &gt;40\u201350, &gt;50\u201360, &gt;60\u201370, &gt;70\u201380, and &gt;80\u00a0ml\/min) was classified as negative or positive shifts, respectively. The number of categories crossed (either positive or negative) determined the grade of shift (of a potential grades 1\u20136, with crossing from one category to the next adjacent category defined as a grade 1 shift) at specific time points compared with baseline: day 4, day 7, and end of therapy (\n                      <jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>\n                      ). Approximately 77%\u201391.6% of patients had either no change or improvement of CrCl across all time points for both treatments. Negative shifts were consistent for telavancin (day 4, 19.3%; day 7, 19.0%;\n                      <jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>\n                      , 23.0%) but increased over time for vancomycin (day 4, 8.4%; day 7, 12.3%;\n                      <jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>\n                      , 19.3%). A significantly lower proportion of patients receiving vancomycin showed renal function decline on day 4 and day 7. At\n                      <jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>\n                      , negative shift rates were similar between treatments (treatment difference 3.6% [95% CI \u22120.7 to 7.9]). At day 7 and\n                      <jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>\n                      , a higher percentage of vancomycin\u2010treated patients experienced high\u2010grade negative shifts relative to telavancin (day 7, vancomycin 2.8% vs telavancin 1.9%;\n                      <jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>\n                      , vancomycin 4.7% vs telavancin 4.1%), though differences were not statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Use of shift tables revealed differences in timing of renal function changes in patients receiving telavancin and vancomycin. Telavancin\u2010related declines in renal function were similar at day 4 and day 7, with a slight increase by\n                      <jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>\n                      . This differed from vancomycin, which caused a steady increase in the percentage of patients with renal function decline over time. A significant difference in negative renal shifts between treatments occurred at day 4 and day 7 and favored vancomycin; however, the difference was minimal and not significant at\n                      <jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.2165","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T02:36:45Z","timestamp":1531449405000},"page":"990-998","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the\n                    <scp>ATTAIN<\/scp>\n                    Trials"],"prefix":"10.1002","volume":"38","author":[{"given":"Boris","family":"Nogid","sequence":"first","affiliation":[{"name":"Theravance Biopharma Inc. South San Francisco California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda K.","family":"Lacy","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc. South San Francisco California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micah","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Romano, Pontzer and Associates Pittsburgh Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Bruss","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc. South San Francisco California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine Nashville Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306801"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.1.213"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2020"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.12.2709"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.05.012"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2014.46.4.219"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R604"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu487"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/430352"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2865-8"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.03.018"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-07"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01110-07"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00712-11"},{"key":"e_1_2_7_17_1","unstructured":"Theravance Biopharma Antibiotics Inc.VIBATIV (telavancin) package insert.South San Francisco CA;2016."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0162-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01568-12"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00927.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2723-2726.2002"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06870909"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318164f781"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1488"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.06.014"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1086\/600884"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05002-14"},{"key":"e_1_2_7_32_1","unstructured":"Hospira Inc.Vancomycin hydrochloride for injection USP[package insert].Lake Forest IL;2015."},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00330"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-183"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir895"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.08.232"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ536"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1442"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1428"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1423"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009337133"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:34:21Z","timestamp":1761068061000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/phar.2165"],"URL":"https:\/\/doi.org\/10.1002\/phar.2165","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]},"assertion":[{"value":"2018-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}